In its first pay-for-delay decision, the UK's Competition and Markets Authority has fined GlaxoSmithKline PLC £37.6m ($54.4m) for alleged market abuse in striking deals to delay the launch of generic copies of its antidepressant Seroxat (paroxetine).
CMA said its decision relates to conduct between 2001 and 2004 in which GSK "agreed to make payments and other...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?